Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
5
|
pubmed:dateCreated |
1995-10-2
|
pubmed:abstractText |
Antiinflammatory activities and modulations of PMNL responses produced by treatment with tetrakis-mu-2-[3-(trifluoromethyl)-phenyl]aminonicotinatodicopper (II) [Cu(II)2(niflumate)4] and niflumic acid were studied in isologous serum-induced rat pleurisy. Doses of 10 or 30 mg/kg (35 or 106 mumol/kg) of niflumic acid or Cu(II)2(niflumate)4 (8 or 23 mumol/kg) caused significant (p < 0.01) reductions in pleural exudate and number of polymorphonuclear leukocytes (PMNLs) in the exudate. While both doses of Cu(II)2(niflumate)4 produced significant dose-related reductions in both parameters, only the higher dose of niflumic acid produced a significant dose-related reduction in both parameters. Boyden chamber measurements of N-formyl-methionyl-leucyl-phenylalanine (f-MLP) chemotaxis by PMNLs incubated with 10 or 30 micrograms/ml niflumic acid (35 or 106 nmol/ml) or Cu(II)2(niflumate)4 (8 or 23 nmol/ml) were significantly (p < 0.01 to p < 0.001) decreased in dose-related fashions. Chemotaxis of PMNLs from pleuritic rats treated orally with 10 or 30 mg/kg niflumic acid or Cu(II)2(niflumate)4 was significantly (p < 0.001) inhibited by the larger dose of niflumic acid and both doses of Cu(II)2(niflumate)4. Opsonized zymosan (OZ)-stimulated chemiluminescence (CL) of PMNLs from pleuritic rats treated orally with these same doses of niflumic acid or Cu(II)2(niflumate)4 was only significantly (p < 0.05 or p < 0.01 respectively) decreased by the larger doses. Superoxide (O2-) production by these cells was significantly decreased by the larger dose of niflumic acid (p < 0.05) while both doses of Cu(II)2(niflumate)4 produced significant (p < 0.05 to p < 0.01) decreases.(ABSTRACT TRUNCATED AT 250 WORDS)
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
May
|
pubmed:issn |
1023-3830
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
44
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
198-203
|
pubmed:dateRevised |
2003-11-14
|
pubmed:meshHeading |
pubmed-meshheading:7655993-Animals,
pubmed-meshheading:7655993-Anti-Inflammatory Agents, Non-Steroidal,
pubmed-meshheading:7655993-Burns,
pubmed-meshheading:7655993-Chemotaxis, Leukocyte,
pubmed-meshheading:7655993-Male,
pubmed-meshheading:7655993-Neutrophils,
pubmed-meshheading:7655993-Niflumic Acid,
pubmed-meshheading:7655993-Organometallic Compounds,
pubmed-meshheading:7655993-Pleurisy,
pubmed-meshheading:7655993-Rats,
pubmed-meshheading:7655993-Rats, Sprague-Dawley,
pubmed-meshheading:7655993-Respiratory Burst,
pubmed-meshheading:7655993-Superoxides
|
pubmed:year |
1995
|
pubmed:articleTitle |
Modulation of polymorphonuclear leukocyte responsiveness by copper (II)2 (niflumate)4.
|
pubmed:affiliation |
Department of Pharmacology-CNRS URA 595, Hôpital Cochin, Paris, France.
|
pubmed:publicationType |
Journal Article
|